{"database": "press", "table": "releases", "rows": [["https://www.warren.senate.gov/newsroom/press-releases/warren-clarke-reintroduce-bill-to-establish-consistent-robust-medical-research-funding", "Warren, Clarke Reintroduce Bill to Establish Consistent, Robust Medical Research Funding", "2024-12-20", "2024", "2024-12", "Democrat", "Senate", "MA", "Elizabeth Warren", "W000817", "www.warren.senate.gov", "warren", "https://www.warren.senate.gov/newsroom/press-releases", "scraper", "Warren, Clarke Reintroduce Bill to Establish Consistent, Robust Medical Research Funding\n\nBicameral bill would protect NIH, FDA funding from Washington funding fights\n\nText of Bill (PDF) | One Pager (PDF)\n\nWashington, D.C. \u2014 U.S. Senator Elizabeth Warren (D-Mass.) and Representative Yvette D. Clarke (D-N.Y.) reintroduced their National Biomedical Research Act, a bill to provide the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) with predictable, robust funding for medical research and development. Senators Ed Markey (D-Mass.), Tammy Baldwin (D-Wis.), Richard Blumenthal (D-Conn.), Tammy Duckworth (D-Ill.), Tim Kaine (D-Va.), Cory Booker (D-N.J.), Bernie Sanders (I-Vt.), and Alex Padilla (D-Calif.) are cosponsors of the bill.\n\nThe National Biomedical Research Act would create the Biomedical Innovation Fund, a new funding stream of $10 billion per year for select initiatives at the NIH and the FDA. The legislation specifies that the Biomedical Innovation Fund should supplement \u2014 not supplant \u2014 existing appropriations for the agencies; funds would only be available during years when Congress increases discretionary appropriations for NIH and FDA, thus ensuring that funding for medical research never falls below Fiscal Year 2024 levels. Fund dollars will also be available through interagency transfer to support research conducted jointly by the NIH or the FDA and other federal agencies.\n\n\u201cThe United States leads the world in biomedical innovation, and so much of that innovation happens in Massachusetts. Big federal investments in medical research and development help make this progress possible,\u201d said Senator Warren. \u201cOur bill would save lives by making sure our researchers have the resources to keep delivering lifesaving breakthroughs and treatments \u2014 regardless of who\u2019s in charge in Washington.\u201d\n\n\u201cI am proud to partner with Senator Warren to reintroduce the National Biomedical Research Act. This legislation would provide researchers with the vital resources they need to continue diagnosing, treating, and preventing a myriad of diseases \u2013 many of which disproportionately impact communities of color. We must always remember sufficiently funding medical research is paramount to the health and safety of the American public,\u201d said Rep. Clarke. \u201cRe-establishing our commitment to supporting scientists and doctors dramatically improves their ability to safeguard our communities against the devastating effects of health care disparities. Let me be clear: this legislation is an opportunity to protect American families proactively, and I believe it is incumbent on us, as members of Congress, to ensure it happens.\u201d\n\nSpecifically, the Biomedical Research Fund established by the bill would supplement yearly appropriations for:\n\nBasic Research: research on the underlying basis of disease to better address disease prevention, diagnosis, and treatment;\n\nDisruptive Innovation: breakthrough research on diseases with unmet medical needs or for which current treatments are limited, inadequate, or burdensome;\n\nAddressing Burdensome Diseases: research on chronic, degenerative diseases that disproportionately contribute to spending under Medicare, Medicaid, Children\u2019s Health Insurance Program, TRICARE, or the Veterans Health Administration;\n\nEarly Career Scientists: grants to young scientists and research institutions supporting these scientists, which lead to earlier research independence and enhance employment opportunities;\n\nImproving Diversity: research conducted by investigators from traditionally underrepresented groups, research in labs of varying sizes, and research at institutions in states that could improve the geographic diversity of funding;\n\nRegulatory Science: research to improve the predictability, consistency, and efficiency of the review of medical products and regulatory decision-making;\n\nMedical Product Surveillance: the development, regulatory review, and postmarket surveillance of new medical products.\n\nThe National Biomedical Research Act has been endorsed by the American Association of Colleges of Nursing, American Heart Association, Fenway Health, Massachusetts Down Syndrome Congress, Society for Behavioral Medicine, Association for Clinical Oncology, Conference of Boston Teaching Hospitals, Public Citizen, UMass Chan Medical School, and ZERO Prostate Cancer.\n\n###", 1, "2026-03-30T01:40:41Z", "2026-04-06T19:07:19Z"]], "columns": ["url", "title", "date", "year", "month", "party", "chamber", "state", "member_name", "bioguide_id", "domain", "scraper", "source", "date_source", "text", "has_text", "collected_at", "updated_at"], "primary_keys": ["url"], "primary_key_values": ["https://www.warren.senate.gov/newsroom/press-releases/warren-clarke-reintroduce-bill-to-establish-consistent-robust-medical-research-funding"], "units": {}, "query_ms": 1.3749529607594013, "source": "dwillis/congress-press", "source_url": "https://github.com/dwillis/congress-press", "license": "MIT", "license_url": "https://github.com/dwillis/congress-press/blob/main/LICENSE"}